Holen Sie sich die Stockscreener-App
6.23
2.20%
-0.14
Vorhandelsmarkt:
6.23
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
What drives Solid Biosciences Inc. stock priceFree Trading Psychology Coaching - Autocar Professional
Is Solid Biosciences Inc. a good long term investmentExponentially increasing returns - jammulinksnews.com
Solid Biosciences Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Cantor Fitzgerald Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
What analysts say about Solid Biosciences Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Solid Biosciences stock rating reiterated at Market Outperform by JMP - Investing.com Canada
What institutions are buying Solid Biosciences Inc. stock nowSteady Income Ideas - beatles.ru
Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com Nigeria
Citi maintains Buy rating on Solid Biosciences stock amid Elevidys safety concerns - Investing.com Canada
Why Solid Biosciences Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
What makes Solid Biosciences Inc. stock price move sharplyFree Investment Group - beatles.ru
Cantor Fitzgerald Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade) - Seeking Alpha
Truist Financial Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm - The Victoria Advocate
For Patients - Solid Biosciences
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - MSN
Solid Biosciences: A Rare Gem in the Gene Therapy Race - AInvest
Solid Biosciences Inc. Initiated with 'Buy' Rating and $14 PT by Citi - AInvest
Solid Biosciences to begin testing SGT-501 in U.S. and Canada (SLDB) - Seeking Alpha
Solid Biosciences cleared to begin phase I studies of SGT-501 in US and Canada - BioWorld MedTech
Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes - Stocktwits
Solid Biosciences receives FDA approval for CPVT gene therapy IND By Investing.com - Investing.com South Africa
Solid Biosciences receives FDA approval for CPVT gene therapy IND - Investing.com Australia
Solid Biosciences gets FDA IND, Health Canada CTA nod for first-in-class cardiac gene therapy CPVT - MarketScreener
Solid Biosciences Gets FDA, Health Canada Clearance to Advance Gene Therapy Trial for Cardiac Disease - MarketScreener
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - The Manila Times
Breakthrough: First Gene Therapy for Fatal Heart Rhythm Disorder Advances to Clinical Trials - Stock Titan
Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid challenges By Investing.com - Investing.com South Africa
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Solid Biosciences Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018SLDB - ACCESS Newswire
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):